Week-24 safety of fostemsavir in heavily treatment-experienced participants with HIV-1 (Study 205888, formerly AI438-047)

被引：0
|
作者：
Kozal, M. [1 ]
Aberg, J. [2 ]
Pialoux, G. [3 ]
Cahn, P. [4 ]
Thompson, M. [5 ]
Molina, J-M [6 ]
Grinsztejn, B. [7 ]
Diaz, R. [8 ]
Lazzarin, A. [9 ]
Gummel, M. [10 ]
Pierce, A. [11 ]
Ackerman, P. [12 ]
Llamoso, C. [12 ]
Lataillade, M. [12 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Hop Tenon, Paris, France
[4] Fdn Huesped, Buenos Aires, DF, Argentina
[5] AIDS Res Consortium Atlanta, Atlanta, GA USA
[6] Hop St Louis, Paris, France
[7] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil
[8] Univ Fed Sao Paulo, Sao Paulo, Brazil
[9] Osped San Raffaele, Milan, Italy
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] ViiV Healthcare, Res Triangle Pk, NC USA
[12] ViiV Healthcare, Branford, CT USA
来源：
HIV MEDICINE | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P31
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [21] Fostemsavir in association with doravirine for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: Data from clinical practice
    Salvo, P. F.
    Steiner, R. J.
    Sanfilippo, A.
    Baldin, G.
    Visconti, E.
    D'angelillo, A.
    Raffaelli, F.
    Dusina, A.
    Di Giambenedetto, S.
    Borghetti, A.
    HIV MEDICINE, 2023, 24 : 172 - 173
  • [22] Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
    Katlama, Christine
    Esposito, Roberto
    Gatell, Jose M.
    Goffard, Jean-Christophe
    Grinsztejn, Beatriz
    Pozniak, Anton
    Rockstroh, Jurgen
    Stoehr, Albrecht
    Vetter, Norbert
    Yeni, Patrick
    Parys, Wim
    Vangeneugdenk, Tony
    AIDS, 2007, 21 (04) : 395 - 402
  • [23] Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Katlama, Christine
    Haubrich, Richard
    Lalezari, Jacob
    Lazzarin, Adriano
    Madruga, Jose V.
    Molina, Jean-Michel
    Schechter, Mauro
    Peeters, Monika
    Picchio, Gaston
    Vingerhoets, Johan
    Woodfall, Brian
    De Smedt, Goedele
    AIDS, 2009, 23 (17) : 2289 - 2300
  • [24] Impact of mild, moderate and severe renal impairment and hemodialysis on temsavir pharmacokinetics following oral administration of fostemsavir, an attachment inhibitor for heavily treatment-experienced HIV-1 infected patients
    Moore, K.
    Magee, M.
    Gunshenan, M.
    Sevinsky, H.
    Llamoso, C.
    Ackerman, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [25] Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
    Eron, Joseph J.
    Clotet, Bonaventura
    Durant, Jacques
    Katlama, Christine
    Kumar, Princy
    Lazzarin, Adriano
    Poizot-Martin, Isabelle
    Richmond, Gary
    Soriano, Vincent
    Ait-Khaled, Mounir
    Fujiwara, Tamio
    Huang, Jenny
    Min, Sherene
    Vavro, Cindy
    Yeo, Jane
    JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (05): : 740 - 748
  • [26] Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTE study
    Ackerman, P.
    Gartland, M.
    Chabria, S.
    Mannino, F.
    Garside, L.
    Kustra, R.
    Clark, A.
    Pierce, A.
    Krystal, M.
    Llamoso, C.
    Lataillade, M.
    HIV MEDICINE, 2019, 20 : 190 - 191
  • [27] Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
    Lalezari, Jacob P.
    Latiff, Gulam H.
    Brinson, Cynthia
    Echevarria, Juan
    Trevino-Perez, Sandra
    Bogner, Johannes R.
    Thompson, Melanie
    Fourie, Jan
    Sussmann Pena, Otto A.
    Mendo Urbina, Fernando C.
    Martins, Marcelo
    Diaconescu, Iulian G.
    Stock, David A.
    Joshi, Samit R.
    Hanna, George J.
    Lataillade, Max
    LANCET HIV, 2015, 2 (10): : E427 - E437
  • [28] Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
    Ogbuagu, Onyema
    Molina, Jean-Michel
    Chetchotisakd, Ploenchan
    Ramgopal, Moti N.
    Sanchez, William
    Brunetta, Jason
    Castelli, Francesco
    Crofoot, Gordon E.
    Hung, Chien-Ching
    Ronot-Bregigeon, Sylvie
    Margot, Nicolas A.
    Wang, Hui
    Dvory-Sobol, Hadas
    Rhee, Martin S.
    Segal-Maurer, Sorana
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [29] Efficacy and safety of doravirine/ islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial
    Mngqibisa, R.
    Khaertynova, I.
    Kumar, P.
    Carr, A.
    Haider, S.
    Zhang, Y.
    Correll, T.
    Asante-Appiah, E.
    Greaves, W.
    HIV MEDICINE, 2023, 24 : 196 - 197
  • [30] DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain
    Sequera-Arquelladas, Sergio
    Hidalgo-Tenorio, Carmen
    Lopez-Cortes, Luis
    Gutierrez, Alicia
    Santos, Jesus
    Tellez, Francisco
    Omar, Mohamed
    Ferra-Murcia, Sergio
    Fernandez, Elisa
    Javier, Rosario
    Garcia-Vallecillos, Coral
    Pasquau, Juan
    VIRUSES-BASEL, 2024, 16 (02):
12345